

S8 Table. Tumor purity and mean depth of sequencing coverage of each sample

Sample No.		Tumor purity (%)	Mean depth (X)
SC01	TCD	40	112.1
	TSD	50	135.5
SC03	TID	60	116.1
	MD	50	98.8
SC05	TCD	50	102.4
	TSD	20	94.1
	MD	20	93.2
SC06	TID	95	116.2
SC07	TCD	65	80.8
	TSD	90	89.8
SC08	TCD	25	99.9
	TSD	95	96.5
SC09	TCD	85	110.3
	TSD	95	134.5
SC13	TCD	20	97.2
	TSD	20	127.2
	MD	40	93.7
SC14	TCD	45	120.2
	TSD	40	110
	MD	15	105.7
SC15	TCD	65	144.5
	TSD	80	60.6
	MD	15	64.4
SC16	TCD	30	100.6
	TSD	20	62.5
	MD	15	92.7
SC17	TCD	20	134.7
	TSD	20	102.4
SC18	TID	30	82
SC19	TCD	25	159.2
	TSD	30	93.5
SC20	TID	85	144.7
SC21	TCD	25	127.5
	TSD	15	123.7
SC22	TCD	60	133.4
	TSD	30	179.2
SC23	TCD	55	128.5
	TSD	95	91.4
SC24	TCD	45	143.2

	TSD	30	116.5
	MD	15	183.9
SC25	TID	40	134.1
	MD	50	119.3
SC26	TID	40	130.3
SC27	TCD	30	153.3
	TSD	20	166.7
SC28	TCD	65	157.8
	TSD	15	156.6
SC29	TCD	20	172.5
	TSD	20	129.3
SC30	TID	70	148.7
SC32	TID	15	175.8
	MD	30	208.6
SC33	TCD	30	151
	TSD	35	124.9
	MD	15	176.2
SC34	TID	20	150.5
SC35	TCD	15	156.8
	TSD	15	113.7
SC36	TID	40	170.6
	MD	20	170.6
SC37	TCD	40	206.8
	TSD	40	171

MD, metastatic tumor; TCD, primary carcinomatous component; TID, primary spindle cell carcinoma or primary biphasic pulmonary sarcomatoid carcinoma with inseparable components; TSD, primary sarcomatous component.